DE102012108598A1 - Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung - Google Patents

Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung Download PDF

Info

Publication number
DE102012108598A1
DE102012108598A1 DE102012108598.6A DE102012108598A DE102012108598A1 DE 102012108598 A1 DE102012108598 A1 DE 102012108598A1 DE 102012108598 A DE102012108598 A DE 102012108598A DE 102012108598 A1 DE102012108598 A1 DE 102012108598A1
Authority
DE
Germany
Prior art keywords
seq
beta
peptide
peptide according
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102012108598.6A
Other languages
German (de)
English (en)
Inventor
Prof. Funke Susanne Aileen
Oleksander Brener
Prof. Dr. Willbold Dieter
Dr. Bartnik Dirk
Dr. Nagel-Steger Luitgard
Antonia Nicole Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Original Assignee
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Juelich GmbH filed Critical Forschungszentrum Juelich GmbH
Priority to DE102012108598.6A priority Critical patent/DE102012108598A1/de
Priority to ES13718522T priority patent/ES2773125T3/es
Priority to EP19170316.4A priority patent/EP3572814A3/de
Priority to DK13719436T priority patent/DK2834644T3/da
Priority to US14/388,865 priority patent/US9591845B2/en
Priority to DK13718522.9T priority patent/DK2834643T3/da
Priority to CN201380018314.8A priority patent/CN104380111B/zh
Priority to CN201810884744.2A priority patent/CN108926749A/zh
Priority to EP13719436.1A priority patent/EP2834644B1/de
Priority to US14/388,869 priority patent/US9464118B2/en
Priority to CN201710626608.9A priority patent/CN107652356A/zh
Priority to ES17172222T priority patent/ES2938886T3/es
Priority to PL17172222.6T priority patent/PL3260865T3/pl
Priority to ES13719436T priority patent/ES2754308T3/es
Priority to JP2015503891A priority patent/JP6434903B2/ja
Priority to PCT/EP2013/057160 priority patent/WO2013150126A2/de
Priority to EP13718522.9A priority patent/EP2834643B1/de
Priority to DK17172222.6T priority patent/DK3260865T5/da
Priority to CN201380018312.9A priority patent/CN104380110A/zh
Priority to EP17172222.6A priority patent/EP3260865B1/de
Priority to JP2015503890A priority patent/JP2015518474A/ja
Priority to PCT/EP2013/057161 priority patent/WO2013150127A2/de
Priority to PCT/EP2013/068992 priority patent/WO2014041115A2/de
Priority to PL17172220.0T priority patent/PL3346273T3/pl
Priority to US14/426,797 priority patent/US20150307552A1/en
Priority to CN201710944015.7A priority patent/CN107556375A/zh
Priority to EP13776426.2A priority patent/EP2895867B1/de
Priority to ES17172220T priority patent/ES2938773T3/es
Priority to DK13776426.2T priority patent/DK2895867T3/da
Priority to ES13776426T priority patent/ES2768264T3/es
Priority to CN201380047981.9A priority patent/CN104704371B/zh
Priority to DK17172220.0T priority patent/DK3346273T5/da
Priority to JP2015531567A priority patent/JP6345670B2/ja
Priority to EP17172220.0A priority patent/EP3346273B1/de
Publication of DE102012108598A1 publication Critical patent/DE102012108598A1/de
Priority to US15/263,728 priority patent/US20160376335A1/en
Priority to US15/433,143 priority patent/US10123530B2/en
Priority to US15/482,968 priority patent/US10167318B2/en
Priority to JP2017134929A priority patent/JP6619394B2/ja
Priority to JP2018098517A priority patent/JP6611858B2/ja
Priority to US16/167,615 priority patent/US10772321B2/en
Priority to JP2018211245A priority patent/JP6861684B2/ja
Priority to US16/200,820 priority patent/US10889618B2/en
Priority to JP2019206147A priority patent/JP6997160B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
DE102012108598.6A 2012-04-05 2012-09-14 Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung Withdrawn DE102012108598A1 (de)

Priority Applications (43)

Application Number Priority Date Filing Date Title
DE102012108598.6A DE102012108598A1 (de) 2012-09-14 2012-09-14 Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
PCT/EP2013/057161 WO2013150127A2 (de) 2012-04-05 2013-04-05 Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
EP19170316.4A EP3572814A3 (de) 2012-04-05 2013-04-05 Polymere; enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
DK13719436T DK2834644T3 (da) 2012-04-05 2013-04-05 Polymerer, indeholdende multivalente amyloid-beta-bindende d-peptider og deres anvendelse
US14/388,865 US9591845B2 (en) 2012-04-05 2013-04-05 Method for treating blood, blood products and organs
DK13718522.9T DK2834643T3 (da) 2012-04-05 2013-04-05 Fremgangsmåde til behandling af blod, blodprodukter og organer
CN201380018314.8A CN104380111B (zh) 2012-04-05 2013-04-05 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
CN201810884744.2A CN108926749A (zh) 2012-04-05 2013-04-05 处理血液、血液产品和器官的方法
EP13719436.1A EP2834644B1 (de) 2012-04-05 2013-04-05 Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
US14/388,869 US9464118B2 (en) 2012-04-05 2013-04-05 Polymers containing multivalent amyloid-beta-binding D-peptides and their use
CN201710626608.9A CN107652356A (zh) 2012-04-05 2013-04-05 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
ES17172222T ES2938886T3 (es) 2012-04-05 2013-04-05 Procedimiento para el tratamiento de sangre, productos sanguíneos y órganos
PL17172222.6T PL3260865T3 (pl) 2012-04-05 2013-04-05 Sposób obróbki krwi, produktów krwiopochodnych i narządów
ES13719436T ES2754308T3 (es) 2012-04-05 2013-04-05 Polímeros que contienen péptidos D multivalentes que se unen a beta-amiloide y su uso
JP2015503891A JP6434903B2 (ja) 2012-04-05 2013-04-05 多価アミロイドβに結合するＤ−ペプチド含有ポリマー及びその使用
PCT/EP2013/057160 WO2013150126A2 (de) 2012-04-05 2013-04-05 Verfahren zur behandlung von blut, blutprodukten und organen
EP13718522.9A EP2834643B1 (de) 2012-04-05 2013-04-05 Verfahren zur behandlung von blut, blutprodukten und organen
DK17172222.6T DK3260865T5 (da) 2012-04-05 2013-04-05 Fremgangsmåde til behandling af blod, blodprodukter og organer
CN201380018312.9A CN104380110A (zh) 2012-04-05 2013-04-05 处理血液、血液产品和器官的方法
EP17172222.6A EP3260865B1 (de) 2012-04-05 2013-04-05 Verfahren zur behandlung von blut, blutprodukten und organen
JP2015503890A JP2015518474A (ja) 2012-04-05 2013-04-05 血液、血液生産物及び器官を処置する方法
ES13718522T ES2773125T3 (es) 2012-04-05 2013-04-05 Procedimiento para el tratamiento de sangre, productos sanguíneos y órganos
JP2015531567A JP6345670B2 (ja) 2012-09-14 2013-09-13 Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用
DK17172220.0T DK3346273T5 (da) 2012-09-14 2013-09-13 Hidtil ukendte d-enantiomer peptider afledt af d3 og anvendelse deraf
US14/426,797 US20150307552A1 (en) 2012-09-14 2013-09-13 Novel d-enantiomeric peptides derived from d3 and use thereof
CN201710944015.7A CN107556375A (zh) 2012-09-14 2013-09-13 新的由d3衍生的d‑对映体肽及其用途
EP13776426.2A EP2895867B1 (de) 2012-09-14 2013-09-13 Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung
PCT/EP2013/068992 WO2014041115A2 (de) 2012-09-14 2013-09-13 Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung
DK13776426.2T DK2895867T3 (da) 2012-09-14 2013-09-13 Hidtil ukendte d-enantiomer peptider afledt af d3 og anvendelse deraf
CN201380047981.9A CN104704371B (zh) 2012-09-14 2013-09-13 新的由d3衍生的d‑对映体肽及其用途
PL17172220.0T PL3346273T3 (pl) 2012-09-14 2013-09-13 Nowe, pochodzące od d3 d-enancjomeryczne peptydy i ich zastosowanie
EP17172220.0A EP3346273B1 (de) 2012-09-14 2013-09-13 Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung
ES17172220T ES2938773T3 (es) 2012-09-14 2013-09-13 Nuevos péptidos D-enantioméricos derivados de D3 y su uso
ES13776426T ES2768264T3 (es) 2012-09-14 2013-09-13 Nuevos péptidos D-enantioméricos derivados de D3 y su uso
US15/263,728 US20160376335A1 (en) 2012-04-05 2016-09-13 Polymers containing multivalent amyloid-beta-binding d-peptides and their use
US15/433,143 US10123530B2 (en) 2012-04-05 2017-02-15 Method for treating blood, blood products and organs
US15/482,968 US10167318B2 (en) 2012-09-14 2017-04-10 D-enantiomeric peptides derived from D3 and use thereof
JP2017134929A JP6619394B2 (ja) 2012-04-05 2017-07-10 血液、血液生産物及び器官を処置する方法
JP2018098517A JP6611858B2 (ja) 2012-09-14 2018-05-23 Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用
US16/167,615 US10772321B2 (en) 2012-04-05 2018-10-23 Method for treating blood, blood products and organs
JP2018211245A JP6861684B2 (ja) 2012-04-05 2018-11-09 多価アミロイドβに結合するＤ−ペプチド含有ポリマー及びその使用
US16/200,820 US10889618B2 (en) 2012-09-14 2018-11-27 D-enantiomeric peptides derived from D3 and use thereof
JP2019206147A JP6997160B2 (ja) 2012-04-05 2019-11-14 血液、血液生産物及び器官を処置する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012108598.6A DE102012108598A1 (de) 2012-09-14 2012-09-14 Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung

Publications (1)

Publication Number Publication Date
DE102012108598A1 true DE102012108598A1 (de) 2014-04-10

Family

ID=49354628

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102012108598.6A Withdrawn DE102012108598A1 (de) 2012-04-05 2012-09-14 Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung

Country Status (9)

Country Link
US (3) US20150307552A1 (enExample)
EP (2) EP2895867B1 (enExample)
JP (2) JP6345670B2 (enExample)
CN (2) CN107556375A (enExample)
DE (1) DE102012108598A1 (enExample)
DK (2) DK2895867T3 (enExample)
ES (2) ES2768264T3 (enExample)
PL (1) PL3346273T3 (enExample)
WO (1) WO2014041115A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
DE102015003503A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Spezifisch Amyloid-Beta bindende Peptide und deren Verwendung für die Therapie und Diagnose der Alzheimerschen Demenz
DE102015003676A1 (de) 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
DE102016125645A1 (de) * 2016-12-23 2018-06-28 Forschungszentrum Jülich GmbH D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz
WO2019070645A1 (en) * 2017-10-02 2019-04-11 Cedars-Sinai Medical Center METHODS AND COMPOSITIONS FOR EFFECTIVE ADMINISTRATION THROUGH MULTIPLE BIOLOGICAL BARRIERS
DE102021121435A1 (de) * 2021-08-18 2023-02-23 Priavoid Gmbh Aß-BINDENDE SUBSTANZEN

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081505A2 (de) 2001-04-06 2002-10-17 imb Institut für molekulare Biotechnologie e.V. Peptid zur diagnose und therapie der alzheimer-demenz
WO2011147797A2 (de) 2010-05-28 2011-12-01 Forschungszentrum Jülich GmbH Hybrid-verbindung, deren verwendung und verfahren zu deren herstellung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355374T1 (de) 2000-11-27 2006-03-15 Praecis Pharm Inc Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
WO2002081515A1 (fr) * 2001-04-03 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. Proteine de liaison de facteur de croissance de type insuline
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
US20070092508A1 (en) * 2005-10-21 2007-04-26 Recombiant Technologies, Llc Detoxification depot for Alzheimer's disease
US8445438B2 (en) 2008-10-27 2013-05-21 Recombinant Technologies Llc Compositions comprising capture peptides for A β-amyloid peptide
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
CN104380111B (zh) 2012-04-05 2017-08-29 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
JP2015518474A (ja) * 2012-04-05 2015-07-02 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングＦｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｊｕｅｌｉｃｈ ＧｍｂＨ 血液、血液生産物及び器官を処置する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081505A2 (de) 2001-04-06 2002-10-17 imb Institut für molekulare Biotechnologie e.V. Peptid zur diagnose und therapie der alzheimer-demenz
WO2011147797A2 (de) 2010-05-28 2011-12-01 Forschungszentrum Jülich GmbH Hybrid-verbindung, deren verwendung und verfahren zu deren herstellung

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Funke et al., ACS Chem. Neurosci. 2010
Needleman, S. B. und Wunsch, C. D. (J. Mol. Biol. 48: 443-453)
Pyruvat Dehydrogenase E1 alpha UntereinheitAccession Nummer YP_006267826 *
Sequenzvergleich der Sequenz SEQ NO:1 mit YP_006267826 *
Smith, T. F. und Waterman, M. S (Adv. Appl. Math. 2: 482-489 (1981))

Also Published As

Publication number Publication date
WO2014041115A3 (de) 2014-06-26
ES2768264T3 (es) 2020-06-22
EP3346273A1 (de) 2018-07-11
JP2015531348A (ja) 2015-11-02
JP6611858B2 (ja) 2019-11-27
PL3346273T3 (pl) 2023-04-11
CN104704371A (zh) 2015-06-10
ES2938773T3 (es) 2023-04-14
US20190085030A1 (en) 2019-03-21
EP3346273B1 (de) 2023-01-04
EP2895867A2 (de) 2015-07-22
US20170313744A1 (en) 2017-11-02
DK2895867T3 (da) 2020-02-03
JP6345670B2 (ja) 2018-06-20
CN107556375A (zh) 2018-01-09
EP3346273A8 (de) 2018-08-29
CN104704371B (zh) 2017-11-07
US10889618B2 (en) 2021-01-12
WO2014041115A2 (de) 2014-03-20
JP2018141008A (ja) 2018-09-13
DK3346273T3 (da) 2023-02-27
EP2895867B1 (de) 2019-10-23
US20150307552A1 (en) 2015-10-29
DK3346273T5 (da) 2024-09-30
US10167318B2 (en) 2019-01-01

Similar Documents

Publication Publication Date Title
EP2834644B1 (de) Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
EP3260865B1 (de) Verfahren zur behandlung von blut, blutprodukten und organen
EP2895867B1 (de) Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung
DE102012102998B4 (de) Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung
EP3747454B9 (de) Amyloid-beta-bindende peptide und diese peptide zur verwendung für die therapie und die diagnose der alzheimerschen demenz
EP3049153B1 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung
EP2903999B1 (de) Peptide zur behandlung und frühdiagnose von morbus alzheimer und anderer tauopathien
EP3271374B1 (de) Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz
DE102012108599B4 (de) A-Beta-Oligomer-bindende Peptide und deren Verwendung
DE102012022013A1 (de) Peptide, die an amino-terminal verkürztes Amyloid-beta-Peptid binden und deren Verwendung
DE102012102999A1 (de) Verfahren zur Behandlung von Blut, Blutprodukten und Organen
DE102014003262A1 (de) Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz
DE102021121435A1 (de) Aß-BINDENDE SUBSTANZEN

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R016 Response to examination communication
R082 Change of representative

Representative=s name: MEISSNER BOLTE PATENTANWAELTE RECHTSANWAELTE P, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee